Stimulatory effects of cardiotrophin 1 on atherosclerosis

Hypertension

Volumn 62, Issue 5, 2013, Pages 942-950

  Konii, Hanae ^a   Sato, Kengo ^a   Kikuchi, Sayaka ^a   Okiyama, Hazuki ^a   Watanabe, Rena ^a   Hasegawa, Akinori ^a   Yamamoto, Keigo ^a   Itoh, Fumiko ^a   Hirano, Tsutomu ^b   Watanabe, Takuya ^a  

^a TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

^b SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

atherosclerosis; cardiotrophin 1; hypertension; macrophages; smooth muscle

Indexed keywords

ACYL COENZYME A; ACYLTRANSFERASE; APOLIPOPROTEIN E; CARDIOTROPHIN 1; CD36 ANTIGEN; CHOLESTEROL ACYLTRANSFERASE 1; COLLAGEN TYPE 1; INFLAMMASOME; LOW DENSITY LIPOPROTEIN; UNCLASSIFIED DRUG; CYTOKINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CELL MIGRATION; CELL PROLIFERATION; ENDOTHELIUM CELL; FOAM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MONOCYTE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; VASCULAR SMOOTH MUSCLE; ANIMAL; AORTA; CELL MOTION; DRUG EFFECTS; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; AORTA; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CELL MOVEMENT; CELL PROLIFERATION; COLLAGEN TYPE I; CYTOKINES; FOAM CELLS; HUMANS; MICE; MICE, KNOCKOUT; MUSCLE, SMOOTH, VASCULAR; SIGNAL TRANSDUCTION;

EID: 84886394834     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.113.01653     Document Type: Article

References (46)

1. Ross R, Agius L. The process of atherogenesis-cellular and molecular interaction: from experimental animal models to humans. Diabetologia. 1992;35 (suppl 2):S34-S40.
2. Allahverdian S, Pannu PS, Francis GA. Contribution of monocyte-derived macrophages and smooth muscle cells to arterial foam cell formation. Cardiovasc Res. 2012;95:165-172.
3. Xu G, Watanabe T, Iso Y, Koba S, Sakai T, Nagashima M, Arita S, Hongo S, Ota H, Kobayashi Y, Miyazaki A, Hirano T. Preventive effects ofheregulin-beta1 on macrophage foam cell formation and atherosclerosis. Circ Res. 2009;105:500-510.
4. Igarashi M, Osuga J, Uozaki H, et al. The critical role of neutral cholesterol ester hydrolase 1 in cholesterol removal from human macrophages. Circ Res. 2010;107:1387-1395.
5. Pennica D, King KL, Shaw KJ, Luis E, Rullamas J, Luoh SM, Darbonne WC, Knutzon DS, Yen R, Chien KR. Expression cloning of cardiotrophin 1, a cytokine that induces cardiac myocyte hypertrophy. Proc Natl Acad Sci USA. 1995;92:1142-1146.
6. Pennica D, Swanson TA, Shaw KJ, Kuang WJ, Gray CL, Beatty BG, Wood WI. Human cardiotrophin-1: protein and gene structure, biological and binding activities, and chromosomal localization. Cytokine. 1996;8:183-189.
7. González A, López B, Ravassa S, Beaumont J, Zudaire A, Gallego I, Brugnolaro C, Diez J. Cardiotrophin-1 in hypertensive heart disease. Endocrine. 2012;42:9-17.
8. Talwar S, Squire IB, Downie PF, Davies JE, Ng LL. Plasma N terminal pro-brain natriuretic peptide and cardiotrophin 1 are raised in unstable angina. Heart. 2000;84:421-424.
9. Talwar S, Squire IB, Downie PF, O'Brien RJ, Davies JE, Ng LL. Elevated circulating cardiotrophin-1 in heart failure: relationship with parameters of left ventricular systolic dysfunction. Clin Sci. 2000;99:83-88.
10. Cottone S, Nardi E, Mulè G, Vadalà A, Lorito MC, Riccobene R, Palermo A, Arsena R, Guarneri M, Cerasola G. Association between biomarkers of inflammation and left ventricular hypertrophy in moderate chronic kidney disease. Clin Nephrol. 2007;67:209-216.
11. Lopez-Andres N, Fortuno MA, Diez J, Zannad F, Lacolley P, Rossignol P. Vascular effects of cardiotrophin-1: a role in hypertension? J Hypertens. 2010;28:1261-1272.
12. López-Andrés N, Rousseau A, Akhtar R, Calvier L, Iñigo C, Labat C, Zhao X, Cruickshank K, Diez J, Zannad F, Lacolley P, Rossignol P. Cardiotrophin 1 is involved in cardiac, vascular, and renal fibrosis and dysfunction. Hypertension. 2012;60:563-573.
13. Tsuruda T, Jougasaki M, Boerrigter G, Huntley BK, Chen HH, D'Assoro AB, Lee SC, Larsen AM, Cataliotti A, Burnett JC Jr. Cardiotrophin-1 stimulation of cardiac fibroblast growth: roles for glycoprotein 130/leukemia inhibitory factor receptor and the endothelin type A receptor. Circ Res. 2002;90:128-134.
14. Calabrò P, Limongelli G, Riegler L, Maddaloni V, Palmieri R, Golia E, Roselli T, Masarone D, Pacileo G, Golino P, Calabrò R. Novel insights into the role of cardiotrophin-1 in cardiovascular diseases. J Mol Cell Cardiol. 2009;46:142-148.
15. Ichiki T, Jougasaki M, Setoguchi M, Imamura J, Nakashima H, Matsuoka T, Sonoda M, Nakamura K, Minagoe S, Tei C. Cardiotrophin-1 stimulates intercellular adhesion molecule-1 and monocyte chemoattractant protein- 1 in human aortic endothelial cells. Am J Physiol Heart Circ Physiol. 2008;294:H750-H763.
16. Fritzenwanger M, Meusel K, Foerster M, Kuethe F, Krack A, Figulla HR. Cardiotrophin-1 induces interleukin-6 synthesis in human umbilical vein endothelial cells. Cytokine. 2006;36:101-106.
17. Fritzenwanger M, Meusel K, Foerster M, Kuethe F, Krack A, Figulla HR. Cardiotrophin-1 induces interleukin-6 synthesis in human monocytes. Cytokine. 2007;38:137-144.
18. Fritzenwanger M, Jung C, Franz M, Foerster M, Figulla HR. Immunomodulatory effects of cardiotrophin-1 on in vitro cytokine production of monocytes & CD4 + T-lymphocytes. Indian J Med Res. 2012;136:471-476.
19. Watanabe T, Nishio K, Kanome T, Matsuyama TA, Koba S, Sakai T, Sato K, Hongo S, Nose K, Ota H, Kobayashi Y, Katagiri T, Shichiri M, Miyazaki A. Impact of salusin-alpha and -beta on human macrophage foam cell formation and coronary atherosclerosis. Circulation. 2008;117: 638-648.
20. Watanabe T, Suguro T, Kanome T, Sakamoto Y, Kodate S, Hagiwara T, Hongo S, Hirano T, Adachi M, Miyazaki A. Human urotensin II accelerates foam cell formation in human monocyte-derived macrophages. Hypertension. 2005;46:738-744.
21. Kang YH, Yang IJ, Shin HM. Herbal formula HMC05 prevents human aortic smooth muscle cell migration and proliferation by inhibiting the ERK1/2 MAPK signaling cascade. J Nat Med. 2012;66:177-184.
22. Quiros Y, Sánchez-González PD, López- Hernández FJ, Morales AI, López-Novoa JM. Cardiotrophin-1 administration prevents the renal toxicity of iodinated contrast media in rats. Toxicol Sci. 2013;132: 493-501.
23. Nagashima M, Watanabe T, Terasaki M, Tomoyasu M, Nohtomi K, Kim-Kaneyama J, Miyazaki A, Hirano T. Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice. Diabetologia. 2011;54:2649-2659.
24. Nagashima M, Watanabe T, Shiraishi Y, Morita R, Terasaki M, Arita S, Hongo S, Sato K, Shichiri M, Miyazaki A, Hirano T. Chronic infusion of salusin-alpha and -beta exerts opposite effects on atherosclerotic lesion development in apolipoprotein E-deficient mice. Atherosclerosis. 2010;212:70-77.
25. Shiraishi Y, Watanabe T, Suguro T, Nagashima M, Kato R, Hongo S, Itabe H, Miyazaki A, Hirano T, Adachi M. Chronic urotensin II infusion enhances macrophage foam cell formation and atherosclerosis in apolipoprotein E-knockout mice. J Hypertens. 2008;26:1955-1965.
26. Testa JE, Chrastina A, Li Y, Oh P, Schnitzer JE. Ubiquitous yet distinct expression of podocalyxin on vascular surfaces in normal and tumor tissues in the rat. J Vasc Res. 2009;46:311-324.
27. Luo X, Xiao Y, Song F, Yang Y, Xia M, Ling W. Increased plasma S-adenosyl-homocysteine levels induce the proliferation and migration of VSMCs through an oxidative stress-ERK1/2 pathway in apoE(-/-) mice. Cardiovasc Res. 2012;95:241-250.
28. Watanabe T, Pakala R, Katagiri T, Benedict CR. Mildly oxidized lowdensity lipoprotein acts synergistically with angiotensin II in inducing vascular smooth muscle cell proliferation. J Hypertens. 2001;19: 1065-1073.
29. Kanome T, Watanabe T, Nishio K, Takahashi K, Hongo S, Miyazaki A. Angiotensin II upregulates acyl-CoA:cholesterol acyltransferase-1 via the angiotensin II Type 1 receptor in human monocyte-macrophages. Hypertens Res. 2008;31:1801-1810.
30. Yajima N, Takahashi M, Morimoto H, Shiba Y, Takahashi Y, Masumoto J, Ise H, Sagara J, Nakayama J, Taniguchi S, Ikeda U. Critical role of bone marrow apoptosis-associated speck-like protein, an inflammasome adaptor molecule, in neointimal formation after vascular injury in mice. Circulation. 2008;117:3079-3087.
31. Latchman DS. Cardiotrophin-1: a novel cytokine and its effects in the heart and other tissues. Pharmacol Ther. 2000;85:29-37.
32. Jougasaki M. Cardiotrophin-1 in cardiovascular regulation. Adv Clin Chem. 2010;52:41-76.
33. Stejskal D, Ruzicka V. Cardiotrophin-1. Review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2008;152:9-19.
34. Pemberton CJ, Raudsepp SD, Yandle TG, Cameron VA, Richards AM. Plasma cardiotrophin-1 is elevated in human hypertension and stimulated by ventricular stretch. Cardiovasc Res. 2005;68:109-117.
35. López-Andrés N, Calvier L, Labat C, Fay R, Diez J, Benetos A, Zannad F, Lacolley P, Rossignol P. Absence of cardiotrophin 1 is associated with decreased age-dependent arterial stiffness and increased longevity in mice. Hypertension. 2013;61:120-129.
36. Moreno-Aliaga MJ, Pérez-Echarri N, Marcos-Gómez B, Larequi E, Gil-Bea FJ, Viollet B, Gimenez I, Martinez JA, Prieto J, Bustos M. Cardiotrophin-1 is a key regulator of glucose and lipid metabolism. Cell Metab. 2011;14:242-253.
37. Beraza N, Marqués JM, Martinez-Ansó E, Iñiguez M, Prieto J, Bustos M. Interplay among cardiotrophin-1, prostaglandins, and vascular endothelial growth factor in rat liver regeneration. Hepatology. 2005;41: 460-469.
38. Lin CS, Lin FY, Ho LJ, Tsai CS, Cheng SM, Wu WL, Huang CY, Lian CH, Yang SP, Lai JH. PKCd signalling regulates SR-A and CD36 expression and foam cell formation. Cardiovasc Res. 2012;95:346-355.
39. Asai S, Saito Y, Kuwahara K, Mizuno Y, Yoshimura M, Higashikubo C, Tsuji T, Kishimoto I, Harada M, Hamanaka I, Takahashi N, Yasue H, Nakao K. The heart is a source of circulating cardiotrophin-1 in humans. Biochem Biophys Res Commun. 2000;279:320-323.
40. Tian Y, Ruan X, Laurikka J, Laine S, Tarkka M, Wei M. The human heart releases cardiotrophin-1 after coronary artery bypass grafting with cardiopulmonary bypass. Scand Cardiovasc J. 2011;45:252-256.
41. Talwar S, Squire IB, O'brien RJ, Downie PF, Davies JE, Ng LL. Plasma cardiotrophin-1 following acute myocardial infarction: relationship with left ventricular systolic dysfunction. Clin Sci. 2002;102:9-14.
42. López B, Castellano JM, González A, Barba J, Diez J. Association of increased plasma cardiotrophin-1 with inappropriate left ventricular mass in essential hypertension. Hypertension. 2007;50:977-983.
43. Natal C, Fortuño MA, Restituto P, Bazán A, Colina I, Diez J, Varo N. Cardiotrophin-1 is expressed in adipose tissue and upregulated in the metabolic syndrome. Am J Physiol Endocrinol Metab. 2008;294: E52-E60.
44. Leosco D, Fineschi M, Pierli C, Fiaschi A, Ferrara N, Bianco S, Longobardi G, Pisani E, Bravi A, Rengo F. Intracoronary serotonin release after highpressure coronary stenting. Am J Cardiol. 1999;84:1317-1322.
45. Schuijt MP, van Kats JP, de Zeeuw S, Duncker DJ, Verdouw PD, Schalekamp MA, Danser AH. Cardiac interstitial fluid levels of angiotensin I and II in the pig. J Hypertens. 1999;17(12 Pt 2):1885-1891.
46. Russell FD, Meyers D, Galbraith AJ, Bett N, Toth I, Kearns P, Molenaar P. Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure. Am J Physiol Heart Circ Physiol. 2003;285:H1576-H1581.